Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Do you consider yourself a contrarian investor? If so, we have just the list for you.

We began by screening the biotech industry for stocks with bearish sentiment from short sellers, with float shorts above 10%.

We then screened these names for those with the confidence of their company insiders, such as members of the board and upper management, with significant net insider purchases over the last six months representing at least 2% of share float. Since most companies only have a handful of company insiders, net insider purchases representing 2% of share float is a big show of confidence in their employer's prospects.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall. More investing ideas on Kapitall Wire.

Do you think these insiders are calling it right? Use this list as a starting point for your own analysis.

List sorted by net insider purchases as a percent of share float.

1. Theravance Inc. (THRX): Engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Market cap at $2.68B, most recent closing price at $27.84. Float short at 13.51%. Over the last six months, insiders were net buyers of 10,104,021 shares, which represents about 20.72% of the company's 48.77M share float.

2. Amyris, Inc. (AMRS): Integrated renewable products company, offers renewable compounds for a variety of markets. Market cap at $207.26M, most recent closing price at $3.64. Float short at 20.51%. Over the last six months, insiders were net buyers of 2,288,360 shares, which represents about 10.88% of the company's 21.03M share float.

3. Repros Therapeutics Inc. (RPRX): Market cap at $139.75M, most recent closing price at $9.42. Float short at 16.26%. Over the last six months, insiders were net buyers of 562,500 shares, which represents about 5.88% of the company's 9.57M share float.

4. Incyte Corporation (INCY): Focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Market cap at $2.37B, most recent closing price at $18.37. Float short at 12.58%. Over the last six months, insiders were net buyers of 4,585,074 shares, which represents about 4.19% of the company's 109.42M share float.

5. ZIOPHARM Oncology, Inc. (ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Market cap at $418.54M, most recent closing price at $5.24. Float short at 14.70%. Over the last six months, insiders were net buyers of 1,923,080 shares, which represents about 3.55% of the company's 54.17M share float.

*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.

Source: Insiders Love These 5 Highly Shorted Biotech Stocks